Solid Biosciences Announces EU Orphan Designation for SGT-212
The European Commission granted orphan designation to Solid Biosciences’ SGT-212, a gene therapy for Friedreich’s ataxia. The company also reported continued progress in the FALCON trial.
Story updates
12:16:17 PM UTC
SquawkNews
Solid Biosciences dosiert fünf Teilnehmer in Phase-1b-Studie mit Gentherapie SGT-212 Solid Biosc
12:16:18 PM UTC
SquawkNews
Solid Biosciences Doses Five Participants in Friedreich’s Ataxia Gene Therapy Trial Solid Biosci